Reference
Health Products Regulatory Authority. XELJANZ (tofacitinib): increased risk of venous thromboembolism and increased risk of serious and fatal infections. Internet Document : 4 Feb 2020. Available from: URL: https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information---xeljanz-(tofacitinib)ea050d2697826eee9b55ff00008c97d0.pdf?sfvrsn=0
Rights and permissions
About this article
Cite this article
Tofacitinib increases risk of VTE and serious infections. Reactions Weekly 1793, 6 (2020). https://doi.org/10.1007/s40278-020-75348-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-75348-0